Q3 2025 Haemonetics Corp Earnings Call
[music].
Good day and welcome to the human Medics third quarter fiscal year 2025 conference call and webcast. At this time all participants are in a listen only mode.
After the Speakers' presentation, there'll be a question and answer session and instructions will be given at that time.
As a reminder, this call maybe recorded.
Speaker Change: I'd like to turn the call over to Olga Guyette, Vice President Investor Relations and Treasury. Please go ahead.
Speaker Change: Good morning, everyone. Thank you for joining us for human attic third quarter of fiscal year, 'twenty 'twenty five conference call and webcast.
Speaker Change: I'm joined today by Chris Simon, our CEO and James <unk>, our CFO.
Speaker Change: This morning, we posted our third quarter and year to date fiscal year 'twenty to 'twenty five results starting back relations website, along with our updated fiscal year 'twenty 25 guidance.
Speaker Change: As usual a quick reminder, that all revenue growth rates discussed today, our organic unless specified otherwise and exclude the impact of currency fluctuation acquisition and divestitures.
Speaker Change: We'll also refer to other non-GAAP financial measures to help investors understand human genetics ongoing business performance.
Speaker Change: Please note that these measures exclude certain charges in income items.
Speaker Change: A full list of excluded items reconciliations to our GAAP results and comparisons with the prior year period. Please refer to our third quarter fiscal year 2025 earnings release available on our website.
Speaker Change: Our remarks today include forward looking statements and our actual results may differ materially from anticipated results.
Speaker Change: Factors that may cause our results to differ include those referenced in the safe Harbor statement in today's earnings release.
Speaker Change: And in our usual SEC filing.
Speaker Change: We do not undertake any obligation to update these forward looking statements.
Chris: And now I'd like to turn it over to Chris.
Chris: Thanks, Olga good morning, and thank you all for joining us.
Chris: Today, we reported third quarter revenue of $349 million growth of 4% on a reported basis and flat organically.
Chris: Third quarter adjusted earnings per share were up 14% at $1 19.
Chris: Our third quarter results reflect the positive effects of our long range plan with another quarter of meaningful earnings growth and margin expansion in hospital, we continue to strengthen our ability to compete in attractive high growth markets with differentiated enabling technology.
Chris: In plasma we are gaining share both in the U S and globally by providing customers with best in class solutions for safely lowering cost per liter.
Chris: Divestiture of our whole blood business helps align our resources to higher margin higher growth opportunities.
Chris: We are achieving significant milestones in the evolution of our business driving improved profitability and growth momentum as we navigate external market challenges, including the temporary pullback in plasma collections.
Chris: Difficult market conditions in China, and rapidly evolving trends in electrophysiology.
Chris: We are increasingly confident in the foundation, we are building for outsized transformational growth.
Chris: All parts of our company contributing to sustainable and profitable long term success.
Chris: Turning to our business unit results, starting with what is now our largest business hospital.
Chris: Revenue grew 24% on a reported basis in the third quarter and 28% year to date with organic growth of 12% and 14% respectively.
Chris: In blood management technologies, our largest hospital franchise revenue grew 10% in the quarter and 11% year to date, driven by sustained market growth share gains and price benefits across the portfolio.
Chris: Hemostasis management had another impressive quarter with 26% revenue growth in the U S. After growing 35% last quarter.
Chris: Growth was driven by improvement in device utilization.
Chris: Growing install base of our TEG success device in the U S with new and existing customers. Following the launch of our global Hemostasis.
Chris: Realization assay cartridge.
Chris: EMEA followed closely with strong growth across all key countries, helping offset continued market challenges in China.
Chris: Transfusion management achieved double digit growth both in the quarter and year to date, driven by new account openings in North America, and EMEA as well as ongoing customer upgrades.
Chris: Latest version upstate trace TX self.
Chris: Cell salvage growth was driven by competitive wins and capital sales as we migrate customers to a higher margin product offering with enhanced features and utility commissions.
Chris: Interventional technologies grew 47% in the third quarter and 58% year to date on a reported basis with 16% organic growth in the third quarter and 18% growth year to date.
In vascular closure was driven by our leadership in electrophysiology, where revenue from Vas Gate MVP investigate MVP XL grew in the mid Twenty's, both in the quarter and year to date.
Chris: We made additional progress in acquiring new accounts and enhancing utilization within existing accounts, including accounts utilizing pulse field ablation technology.
Chris: Escape MVP XL is a game changer, allowing us to capitalize on emerging catheter based ablation technologies and expand our share in la AAC procedures.
Chris: With the EP market opportunity remaining only halfway penetrated we are confident we will continue to gain share.
Chris: Continued competition in coronary and peripheral procedures lowered our growth and small bore arterial closure and weighed on our overall <unk>.
Chris: C growth rate.
Chris: This is a mature market with low single digit growth that contributes less than 15% of our VC revenue.
Chris: And we are now taking steps to improve our performance and drive more favorable results.
Chris: Revenue from sensor technologies, and esophageal coolly contributed 12% to hospital reported revenue in the quarter and 16% year to date.
Chris: While we're making progress in these markets. We acknowledged that we are falling short of our own ambitious targets.
Chris: In part to external market disruptions, we remain confident in the potential of these products and we are committed to realizing their commercial and financial benefits.
Chris: We see significant market opportunities and expect robust growth in this business driven by our leadership in EP with MVP and MVP Nextel and continued momentum with TEG success. However, we need to further strengthen our commercial and clinical capabilities to establish our leadership across.
Chris: The newly acquired products. Accordingly, we are updating our hospital revenue guidance to a new range of 24% to 46% on a reported basis.
Chris: 12% to 14%.
Chris: Organic basis.
Chris: Moving to plasma and blood center due to the planned CSL transition plasma revenue declined 9% in the quarter and 5% year to date with North America disposables revenue down 11% in the quarter and 6% year to date excluding.
Chris: Excluding CSL use disposables revenue grew in the quarter driven by premium pricing from technology upgrades share gains and collections growth.
Chris: After a slight decline in Q2 U S collections volumes, excluding CSL and share gains grew low single digits for the third quarter and 4% sequentially in line with historical seasonality as our customers focus on reducing cost per liter and benefit from increased center.
Chris: Efficiency, and 9% to 12% higher plasma yield as they transition to our latest technology.
Chris: Okay.
Chris: Revenue growth in Europe within the double digits, driven by both share gains and robust collections environment. It is important to note that the CSL transition is for U S disposables and equipment, we continue to supply all of Csl's Dms software in the U S and all of their equipment and disposables in <unk>.
Chris: Europe.
Chris: We are excited to announce that we have signed new long term agreements with biolife and with referrals reinforcing our continued close partnership and highlighting our ability to bring innovation to plasma collections.
Chris: Both agreements are centered around gaining market share through adoption of our winning technology. Both in the U S and globally and collaborating on innovation over the coming years, we made meaningful progress transitioning both customers to persona and express plus in the third quarter.
Our technologies offer unmatched opportunities for cost reduction throughout the plasma collection center, while maintaining the highest standards of donor safety with over 90 million collections on Nexus Pcf's 40 million persona and now over $1 million on express plus we are establishing Ria.
Chris: <unk> world evidenced that sets us apart from our competition.
Chris: Our innovation is transforming the EBITDA profile of our collections business, making it significantly more profitable and well positioned.
Chris: To contribute to ongoing company wide margin expansion.
Chris: We remain confident in the long term sustainable revenue and earnings growth contribution from our plasma business.
Chris: End market demand for plasma derived therapies is strong and we see high single digit compound annual growth in fractionation capacity through 2032.
Chris: As customer yield benefits annualized.
Chris: Productivity takes effect, we expect collection volume to fully recover we are well positioned to outperform the growth in the plasma collections market by gaining share and expanding margins through innovation that helps customers safely reduce costs and improve donor satisfaction we are updating.
Chris: Our organic plasma revenue guidance to a 5% to 7% decline inclusive of approximately $100 million from CSL use disposables.
Chris: Loved center revenue declined 3% in the third quarter and 2% year to date, primarily due to the whole blood portfolio rationalization.
Chris: <unk> revenue grew 5% in the quarter and 3% year to date, driven by global plasma share gains and strong U S. Red cell collections, partially offset by fewer capital sales international demand for source plasma is expanding following an in depth head to head compare.
Chris: A live evaluation in our third quarter, we were selected as the exclusive supplier of plasma collection solutions to our largest customer outside the U S. Japanese spread cross this competitive win underscores the competitive strength of our Nexus PCF technology offering.
Chris: Combined with the divestiture of our whole blood business. This positions us to meaningfully improve long term revenue and margin growth for this business.
Chris: The impact of the whole blood divestiture in our fourth quarter. We are updating our reported revenue guidance to a decline of 7% to 9%, while reducing organic decline to 2% to 4%.
Chris: Before I handover the call to James I'd like to offer you additional remarks.
Chris: While we revised our revenue guidance to 3% to 5% growth on a reported basis and flat to 3% organic we remain confident in the steps we are taking to ensure sustainable long term growth at attractive margins our record third quarter margins demonstrate that our strategy is working.
Chris: And we expect further margin expansion over the remainder of our long range plan.
Chris: This year has presented significant external challenges, but we take pride in how we've responded we don't control external market disruptions. However, we've consistently found ways to adapt and drive progress as plasma collection slowed we accelerated technology adoption and gain market share we.
<unk>, new assays and bolster our performance with TEG success to mitigate shortfalls in China in vascular closure, we introduced <unk> MVP XL to help enable emerging ablation trends enhancing both our product relevance and commercial capabilities throughout.
James: We remain focused on innovation, ensuring strong results and long term success, we are confident in our ability to drive profitable growth and value creation and we're excited about the opportunities ahead as we execute our vision in FY 'twenty six and beyond now over to you James.
James: Thank you, Chris and good morning, everyone.
James: Chris has already discussed our business units and company revenue. So now I will discuss the rest of our financial results and updates to fiscal 2025 guidance.
James: In the third quarter, our adjusted gross margin was 57, 7%.
James: An increase of 240 basis points compared to the prior year driven by favorable volume growth in hospital, improving portfolio mix and pricing across all business units, partially offset by a 30 basis point impact from foreign exchange.
James: Year to date, our adjusted gross margin was 56, 6%, reflecting a 210 basis point improvement year over year with the same growth drivers as in the quarter, but at a slightly higher impact from FX and approximately 70 basis points are.
James: Our portfolio transformation is delivering the expected impact on our margins.
James: We anticipate continued improvement for the remainder of this fiscal year and beyond supported by momentum in the hospital business improving profitability of our plasma business and the divestiture of the previously margin dilutive whole blood franchise.
James: Adjusted operating expenses in the third quarter were 111 $5 million, an increase of $1 2 million or 1% compared with the third quarter of the prior year.
James: As a percentage of revenue adjusted operating expenses were at 32% down 150 basis points when compared with the same period last year.
James: Additional growth investments were more than offset by an increasing operating leverage and lower performance based compensation.
James: Adjusted operating expenses year to date were $338 7 million.
James: An increase of $23 9 million or 8% compared with the prior year and 32, 9% of revenue.
James: The dollar increase in adjusted operating expenses was primarily due to the acquisitions, the offsets and tuned medical as well as additional investments to support growth.
As a percentage of revenue adjusted operating expenses remained relatively flat compared to the same period last year.
James: Adjusted operating income for the third quarter was $89 4 million.
A $16 1 million increase or 25, 7% of revenue a new company record.
James: This reflects a 150 basis point sequential expansion from the prior quarter.
And at 390 basis point increase year over year, including a 40 basis point impact from FX.
James: Year to date adjusted operating income was $244 million.
James: $32 million or 23, 7% of revenue an increase of 180 basis points compared to the same period last year.
James: Key drivers included a higher margin portfolio.
James: Increased leverage as we scale and accelerate growth and lower performance based compensation.
James: We are confident in our ability to deliver continued margin expansion and we are updating our fiscal 'twenty five adjusted operating margin guidance to the high end of our previous range at approximately 24%.
James: With stronger margin anticipated in the fourth quarter. This sets the foundation for ongoing margin growth into fiscal 2006, as we work towards achieving our target of high <unk> adjusted operating margins outlined at our 2022 Investor day.
James: The adjusted income tax rates were 25% in the third quarter, and 24% year to date, compared with 25% and 23% and this corresponding periods last year.
We anticipate full year adjusted income tax rate to be approximately 23%.
James: Third quarter fiscal 'twenty five adjusted net income was $63 million up.
James: Up $7 million or 13% and adjusted earnings per diluted share was $1 19.
James: 14% when compared with the same period of fiscal 'twenty four.
James: Year to date adjusted net income was $169 9 million.
James: Up $12 3 million or 8% and adjusted earnings per diluted share was $3 32.
James: Up 8% when compared with the same period in fiscal 2004.
James: The combination of the adjusted income tax rate.
James: <unk> expense net of interest income changes in the share count and FX added 13.
James: Unfavorable impact in the third quarter.
James: And a 33.
James: Unfavorable impact year to date, when compared with the prior year.
James: Despite some changes to our revenue guidance, we anticipate strong earnings performance to continue as we tightened our adjusted EPS guidance range to $4 50.
James: Two $4 70.
James: Before discussing the balance sheet I'd like to provide additional context on the recent sale of our whole blood franchise.
James: This strategic divestiture helps us better align our portfolio with our focus on winning markets.
James: Leading positions and strong financial performance and we expect it to positively impact revenue growth and margin expansion, while enabling our teams to fully focus on high growth opportunities in line with our long term vision.
James: We believe GBS is a natural owner of this business and we look forward to collaborating with them throughout the transition and beyond.
Our guidance includes approximately $49 million in revenue from whole blood, reflecting a 32% decline compared to the prior year on a reported basis with no impact on adjusted EPS as we expect to fully offset the impact of this divestiture.
James: With additional planned savings in fiscal 'twenty five.
Fiscal 'twenty six.
James: Moving to balance sheet and cash flow.
James: In the first nine months of fiscal 'twenty five we recorded cash provided by operating activities of $65 2 million down from $117 7 million in the same period last year.
James: And free cash flow of $49 7 million.
James: Compared with $62 3 million in the same period of fiscal 'twenty four.
James: This decline was driven by an increase in working capital largely due to higher inventory levels digital transformation costs and the timing of certain payments that occurred in our fiscal first quarter.
James: Despite lower cash flow year to date, we expect to finish fiscal 2005 with strong free cash flow and we have updated our guidance to a new range of $120 million to $140 million.
James: Cash on hand at the end of the quarter was $328 million.
James: $142 million since the beginning of this fiscal year, primarily due to our recently completed debt transactions and partially offset by our acquisition of attune medical and share buybacks.
James: There were no changes to our debt structure in the quarter.
James: And no outstanding borrowings on our revolving credit facility.
James: <unk> in our net leverage ratio of approximately 242 times EBITDA as defined by our credit agreement.
James: In closing I'd like to reiterate that we are in a stronger portfolio position than ever with every business contributing towards margin expansion and accelerating revenue growth in years to come in fact, all three of our business units are expected to exit fiscal 'twenty five.
James: At improved margins with further opportunities for growth ahead.
James: The underlying markets are strong and we expect growth in U S plasma collections to fully recover to a historical average growth rate in the high single digits.
James: In vascular closure, we expect TSA throughout the net positive impact on our business as growth in the treatment of atrial fibrillation procedures more than offsets any changes in the number of access points.
James: We are winning with our technology, including bleeding in head to head competition and plasma accelerating our success in vascular closure with MVP and MVP excel and changing the standard of care in viscoelastic testing with our point of care system.
James: <unk> six <unk>.
James: And finally with an existing capacity of nearly $1 billion and our strong balance sheet, we will remain opportunistic and capital allocation.
James: Focusing on value creation, including organic growth.
James: Synergistic tuck ins and share repurchases.
James: M&A is key to our long term success and we are committed to capitalizing on the benefits of newly acquired products and future strategic tuck in in our pipeline.
James: We are excited about the future and remain focused on delivering long term value for our shareholders.
James: Thank you and we are now ready to open the call for Q&A.
Thank you if you'd like to ask a question. Please press star one one.
James: If your question has been answered and you'd like to remove yourself from the queue. Please press star one again.
James: One moment for questions.
Speaker Change: And our first question comes from Anthony Petrone with Mizuho Financial Group. Your line is open.
James: Thanks.
Speaker Change: Hope, everyone is doing well and Chris.
James: <unk>.
James: The Philly Philly pushing peer there on the Super Bowl on Sunday, So hope your team wins, maybe I'll start with plasma and then shift over to <unk>.
James: On plasma maybe can we walk through a little bit on decoupling.
James: Where CSL contribution was in the quarter I think the math is suggesting that they've rolled off faster than.
James: Initially forecasted earlier in the year.
Speaker Change: And then again those underlying trends I think you mentioned, Chris that underlying plasma grew 4%, but you have talked about share gains. So maybe just looking at that number a little bit more closely like how much of share gain how much is price and we're always actually underlying volume just to clean that up a little bit and I'll have a follow up on that.
James: Gabe.
Gabe: Yes, Anthony Thanks.
James: Bill Bird.
James: CSL.
James: Performing <unk>.
James: Exactly on line with what we guided to last May we thought it would be.
James: It was approximately.
James: Approximately $100 million Thats still where we believe it is it's a 70 30 split meaning 70% of that was realized in the first half of our fiscal year.
James: With the remaining 30% so that transition is largely on track.
James: Progressing as planned.
James: They are complying with the contract so no changes no issues there in terms of the rest of the field.
James: What we saw in the second quarter in the third quarter was growth sequentially consistent with our historical seasonal averages in terms of volume.
James: We add on top of that is share gains specifically at Biolife.
James: Cripples and then the ongoing technology upgrade, which we communicated last quarter, we expect to have substantially complete.
James: On persona by the end of this fiscal year, that's a key milestone for a long time now we've been talking when when will the rest of the field adopt so for the next 60 days the rest of the field, we will have adopted and you see that coming through.
James: <unk> role in margin expansion is quite significant because of the innovation premium there.
James: Okay and then just.
James: Just lastly, I guess the last piece on.
James: Base volumes obviously.
James: We've been talking about quite a bit that there was a safety stock replenishment phase.
James: It seems like that specifically is the slow the reason for the slowdown in volumes is there anything else that you can point to structurally and then just quickly on <unk>.
James: Last quarter the the outlook for second half was high <unk> I think you are coming into the mid Twenty's here.
James: Within <unk>, so maybe just a little bit about the XL push how many accounts have adopted at this point.
James: And is there any.
James: Can you maybe walk us through the bridge from high <unk> to mid twenties.
James: That shift Q over Q.
James: Yes, Thanks, Anthony I look on plasma collection volumes I think theres a lot of hand wringing out there in the market it's misplaced.
James: We observe our leading collectors doing at the moment is capitalizing on the innovation premium and the technology upgrades. So we gave them an immediate boost in most cases in excess of 10% when we rolled this out to the smaller collector earlier in the cycle, but you took that 10 and added another 10 in there.
James: Year to date productivity and we're off to the races, and that's what fuels the pace of the recovery now the focus is cost per liter as they get closer to their target inventory levels. So.
James: A key enabler of that however, as they begin to lap those productivity improvements. We expect this to return to historic seasonal averages and I step back from it all there's always been a lot of noise in the system I said that at JP Morgan and people got kind of anxious about the reality is the number.
James: Moves up and down in any given period based on the vagaries and the challenges individual collector space. We look at a number of factors, including the discrepancy between the growth in demand compound annual growth rate for <unk> based therapy with the long term growth in collections and there is at least a 200 basis.
James: Point differential between the two with collections lagging so we know they need to continue to run hard against that when we look at the planned expansion between now and 2032, we know that there's going to be a mid to high single digit growth in fractionation expansion, which accompanies the advancements in <unk>, particularly in primary.
James: In secondary immune deficiency that accompanies the ongoing uptick in subcutaneous, which requires 20% to 25% more plasma on dose equivalent basis. So we look at that high single digit growth in the capital expenditures against that and feel very confident within the existing network that with our technology we can.
James: Help restore collections growth and deliver against it so yes.
James: Temporary pullback, we believe it's temporary theres nothing structural our team to their credit is capitalizing on the low to get new technology rollout gain share such that as collection volumes recover will be that much better position. So we're very bullish on where plasma going intermediate to longer term. There is no worries there.
On last gait XL products a game changer, we're excited about what we're doing there we're more enthusiastic and we set bold.
James: Aggressive goals for our team to deliver we see vast gate MVP investigate XL tracking very powerfully.
James: Fab oblations, including with the newer modalities on PSA, we've had a bit of a lag on vast scale, which is predominantly used in PCI and I think we've just got yes. There is competition there has always been competition.
James: We have.
James: Our young and relatively inexperienced sales team that's working up the learning curve of multitasking across we will deliver against it.
James: Anything we're not getting done in the current period will be that much more of an opportunity for us in FY 'twenty six and beyond so the products excellent markets right and so we need to just execute against it which I'm confident we will going forward.
James: Thank you.
James: Okay.
James: Thank you. Our next question comes from Robert <unk> with Jpmorgan. Your line is open.
Robert: Hi, Thanks, so much for taking the question I guess the first one I had was just falling up on Anthony's question.
Speaker Change: On vast Gabe I think you mentioned a.
Robert: Roughly 12%.
Robert: Revenue contribution from new products.
Robert: Which by my math and maybe just this might require a clarification gets to still doesn't really get us to the mid twenty's vascular closure growth in the quarter. So maybe you could just clarify that to start and then also just if you could provide any commentary on the PSA attach rate I guess, what are you hearing from doctors.
Robert: Now that you have <unk> on the market and what's the relative growth contribution from PFA and enclosure.
Yes, Ron Thanks for the question the mid Twenty's that we've talked about in the prepared remark that I just touched upon is a breakout of MVP and MVP, XL, which really constitutes the portfolio's role in ablation therapy.
Robert: The additional number in your back of the envelope math is not far off is adding investigate which is really.
Robert: It's kind of pulled that back the new products that you spoke about yes. There is a challenge with the new products and we're working our way through.
Robert: Getting those on track, they're falling short of our own ambitious expectations Theres nothing wrong with the product there's nothing wrong with the markets. It is challenging.
Robert: <unk> is a disruptive influence for Enzo ATM, specifically, but there is a way to work through that and we're actioning that now.
Robert: Yes, Brian this is Jim.
Yes.
Speaker Change: I can hear the 12% that youre referencing that the contribution from M&A products to the reported growth rate.
Robert: Just wanted to make that clear so it's.
Robert: It's a very different number than the basketball closer gross invested MVP and MVP XL.
Robert: Got it that's helpful. Thank you and then I guess my follow up was just on on margins and free cash flow you had pretty healthy operating margin expansion in the quarter.
Robert: But obviously at a bit of a shortfall in free cash flow and brought that guide down for the year. I guess can you just talk a bit more about the discrepancy there how much of that is temporary and I guess you mentioned an increase in working capital, but what gives you confidence that you can eventually improve free cash flow.
Robert: Beyond the quarter and then into fiscal 'twenty six.
Robert: Yeah. Thanks, Thanks, Brian Yes, we had.
Robert: Very strong operating margin.
Robert: Performance in the quarter as we were very pleased with that sets us up nicely.
Robert: Our future.
Robert: Goals in 2006 in terms of cash flow.
Robert: What gives me confidence they're really on that working capital number is is that this fiscal year.
Robert: There were a lot of dynamics, mostly in <unk>.
Robert: <unk>.
Robert: And we used the year.
Robert: To replenish our Nexus inventory, so our accounting whenever we purchased a new Nexus system. It goes into inventory first and that's the biggest.
Robert: The biggest chunk.
Robert: The increase in inventory the other the other thing that I don't expect to.
Replicate.
Robert: Or duplicate next year is.
Robert: We started the year our plasma inventories were.
Robert: Very very low and we were at a point, where we were up we were essentially hand to mouth. We had depleted our finished goods inventories as we were supplying the market.
Robert: And we use this year to replenish those inventories, which.
Robert: As you know.
Robert: Use of cash so.
Robert: I think those are those are the two the two big two biggest drivers beyond that.
Robert: There is always going to be issues with timing on.
Robert: Collections and payments so those will roll off will go up and down.
Robert: But but but the inventory piece of it is the one that.
Robert: Shouldnt recur and we'll look to see improvements in.
Robert: Free cash flow as we as we move forward.
Robert: Thank you.
Robert: Thank you.
Speaker Change: Next question comes from Murray Tivo with BTG. Your line is open.
Murray Tivo: Hi, good morning, Thanks for taking the questions.
Murray Tivo: Wanted to start here, maybe on the blood management Technologies segment, you mentioned increased utilization increased installed base in <unk>.
Murray Tivo: And it's a bit of a tailwind from this new assay cartridge with strong performance in the U S and EMEA, but weakness in China, I Wonder if we could get a little bit more detail around some of that how sustainable do you think this.
Murray Tivo: Tailwind is for the U S and EMEA.
Murray Tivo: With the new assay cartridge.
Speaker Change: What is your expected timeline on the China weakness any other details around that business would be helpful.
Speaker Change: Thanks Marie.
We are very bullish on blood management technologies, we have made a leadership change there last year that team has dialed in and they are really delivering they've taken the <unk> neutralization of the global assay and just run with it here in the states, which is what you see in terms of 35% last quarter mid <unk> this quarter. So.
Speaker Change: Yes, I think there is room to run with that team and with that product and youre seeing that delivery, which is really helping.
Speaker Change: The European team has found their stride as well and is picking up we will bring that assay to Europe theres plans underway that we're executing against that so we expect continued robust growth across the base of those two.
Speaker Change: Also getting good growth from our other products transfusion management in the quarter cell salvage. So it's a nice overall package that that team is delivering against China is unique right, China is less than 5% of our global revenue that.
Speaker Change: And that revenue is split 50, 50 between Blood Center and hospital Blood center businesses impact and doing well within the hospital. It's split roughly 50 50 again between transfusion.
Speaker Change: Hemostasis management and cell salvage cell salvage is fine the issue very specifically is hemostasis management and it's evolved over the course of the last year from the various localization efforts.
Speaker Change: Yes kind of.
Speaker Change: Specific controls confusion in the market to significant cutbacks in reimbursement and we don't expect that to get better.
Speaker Change: That's really challenged market.
Speaker Change: We're grateful that our exposure is quite minimal there.
Speaker Change: From our vantage point, we will deliver in the markets, where the products valued and rehab reimbursed appropriately.
Speaker Change: As we lap the China, Comparables I think youll see that performance in our FY 'twenty six really come to the fore.
Speaker Change: Okay got it.
Speaker Change: And then I wanted to ask a follow up here on the Biolife and gristle contracts any more quantitative details that you can offer around that in terms of how long those are for what amount of market share that that opens you up to any details on what this might add to kind of core plasma.
Growth year over year any other details I think it is an encouraging sign.
Speaker Change: Yes, we agree Marie it's a very encouraging sign and I'd say more broadly again about the team and about the product anyone who has done a detailed assessment of our Nexus platform has chosen nexus period full stop so we're optimistic about that win.
<unk> AG peripherals in Biolife.
Speaker Change: Long duration contracts.
Speaker Change: Five to seven plus years.
Speaker Change: They tend to be tiered pricing that works.
Speaker Change: In two ways more volume is better for everybody involved and we reflect that in the pricing and then higher utilization better turn rates better return on invested capital and we're really pleased with the nature of the partnerships that have evolved in and around these extended agreements and so.
Speaker Change: We would be surprised and disappointed if we werent the majority share players in each of those accounts going forward and so.
Speaker Change: I'll leave it at that for now, but the relationships across the board have never been stronger the products delivering fully and we expect to capitalize arent.
Speaker Change: Okay I appreciate the details thanks, so much.
Speaker Change: Thank you. Our next question comes from David <unk> with citizens JMP. Your line is open.
David: Hey, good morning.
Speaker Change: Alex has been jumping around a couple of calls but.
Speaker Change: Chris I wanted to just make sure I heard something correctly so.
Speaker Change: You said.
Speaker Change: Looking out over the next seven years mid.
Speaker Change: Mid to high single digit growth in collections for plasma is sort of what's the anticipated I guess.
Speaker Change: I know you don't want to give forward guidance, but.
Speaker Change: It sort of be a floor for what your growth there it looks like.
Speaker Change: As we look ahead correct I mean, there is not a reason once you're past CSL.
Speaker Change: Yes.
Speaker Change: Alright, just be clear the mid to high single digit compound annual growth rate through 2032 is in committed fractionation capacity. So this is what our customers have announced publicly is their intention in terms of expanding their capacity, we like the number.
Speaker Change: I can quote just several thousand clinical trials for <unk> I can talk about the fact that the existing network is operating still at 80%, which gives meaningful room to expand without new center openings. Although some of our customers are stepping up the new center openings again now.
Speaker Change: They are all interesting stats powerful stats I can talk about the growth in primary and secondary.
Speaker Change: But at the end of the day, they don't commit to multibillion dollar capital expansions unless they believe there is end market demand. So that's.
Speaker Change: When we go back past this over decades, the fractionation capacity tends to be a very good proxy for what you described as the floor and then we built on that based on what we can achieve whether it's.
Speaker Change: More plasma needed productivity through those centers.
Speaker Change: Do those plants, which we know is the case and has been communicated by our customers on top of meeting that the added demand for subcutaneous <unk>.
Speaker Change: Being able to collect.
Speaker Change: The fractionation demand our ability to gain share and then of course, the price premium, which we're very pleased we've been able to command for our superior technology.
Speaker Change: And then just one other quick clarification.
Speaker Change: The change in the guide for Hospital I think you said it was not related to.
Speaker Change: Hey, good vascular closure is that correct.
Speaker Change: Yes taken vascular closure are doing well.
Speaker Change: TEG is doing exactly what we needed to do and then some covering its own challenges in China, which will lap here shortly and it gets more favorable vascular closures.
Speaker Change: Multi faceted right, we're very pleased with MVP and MVP XL, which is our primary ablation play so despite the PFA disruption, we're doing what we need to delivering where we can growing commensurately, where we need to get better is on vast gate, which is primarily.
Speaker Change: Interventional cardiology and I think it's.
Speaker Change: The product has competition, it's a very good product, but it needs attention and Thats why were doing the expansion and the development work clinically and commercially to make sure bascay delivers folio on its potential as well, it's 15% one five of the vascular closure opportunity, but it is a large market and it is still very much.
Speaker Change: Untapped market. So we know we can do better there.
Speaker Change: Thank you.
Speaker Change: Thank you. Our next question comes from Andrew Cooper with Raymond James Your line is open.
Speaker Change: Yeah.
Everybody. Thanks for the time, I wonder maybe stick with that.
Speaker Change: Vasquez discussion here for a second so I just want to make sure. The math math is right and maybe get a little bit more context. So that you can offer on ETE growth essentially being in the mid twenties it implies that that.
Speaker Change: Regular vast gain if we'll call it that or the IC component there was down pretty substantially I don't think we've necessarily.
Speaker Change: None that to be the case.
So maybe just a little bit more color on what's driving that.
Speaker Change: Declines there are you losing competitive share is there something thats changed in that competitive environment over the last.
Speaker Change: A couple of quarters or what's going on in that.
Speaker Change: Admittedly smaller sub segment of the market.
Speaker Change: Yes, Andrew you've got it right.
Speaker Change: The 85% of ablation doing well will continue to propel us on that 15% I think we've got a couple a few things going on one is there is.
Speaker Change: A step up in competition when a product is vast gate is now in all its forms approaches $200 million in the hospital you start getting attention from competitors and we clearly welcome them up and that's a good thing when you capitalize more on that because that's more share of voice.
We just need up our game in terms of competitive wins I think the other factor is an internal factor as we build out we will solve this but from where we sit we are slightly under resource and interventional cardiology, particularly in structural heart and we're committed to delivering for example, and savvy wire as one of the acquire.
<unk> products, we've really ramped up its extensive training theres real time in procedures working with.
Speaker Change: Interventional list as they go through.
Speaker Change: The unintended consequence of that has been a temporary loss of focus on basket same.
Speaker Change: Target set.
Speaker Change: Sales force, but a different procedure base and so we've got to correct for that we are and I think the investments. We have planned that are part of our ongoing commercial built will give us the mind share and the resources to correct that problem in short order.
Speaker Change: Okay. That's helpful.
Maybe next knowing full well.
Speaker Change: Tariff situation is let's say dynamic.
Speaker Change: What's the latest thinking in terms of potential contingency plans, if something major goes into effect in Mexico or how.
Speaker Change: Whether it's a question of say, 25% or that range might translate to an impact on profitability given the manufacturing presence you have south of the border.
Speaker Change: Yes, Andrew I think we're grateful that we are running on a fiscal year basis and don't have to guide for.
Speaker Change: The year to come at this point given how dynamic the situation is we're obviously paying close attention to that.
Speaker Change: Bunch of modeling I'd say three things upfront.
Our favorite because we've seen something at some news out there, which is just erroneous about our relative exposure. The first thing is we have no exposure to China zero I talked about the revenue base. There. That's separate that's very modest we don't manufacture in China, we do not supply from China, and we have zero exposure to the tariffs that have gone into effect there on top of what was already there.
Speaker Change: Before.
Speaker Change: As we think about Mexico, and Canada, we have exposure and I'll talk about that but it is important to remember we made a $30 million capital investment in our Pittsburgh, Pennsylvania facility and that is the home and state of the art operation for plasma bowls and <unk> cartridges are two fastest running.
Speaker Change: Skus. So we feel very good about that fully automated operation Thats, an absolute hub for us.
Third thing I would say positively that seems to be getting missed is the divestiture of whole blood is very helpful. That was a product that was predominantly produced in Mexico assembled in Mexico, and transferring that to a more rightful owner better positioned to deal with the opportunity set there eliminates that threat what we have.
Speaker Change: Left is the blood center business and T J, Tijuana and Thats, an exposure for us because we don't have a ton of price elasticity on that business sells.
Speaker Change: Cell salvage is also there, but we're talking about in aggregate.
Speaker Change: Slightly more than $200 million in revenue, we care about it we want to manage it but its an exposure I think the other thing to think about his intervention technologies, which is a mix of Mexico and.
Speaker Change: Canada in that case, we have plans to expand our manufacturing footprint. That's part of the ongoing integration and we will we will get out of that exposure is the expansions arent in either of those two geographies and the interim that's where we do have the most price elasticity. If we need to go there the products are priced competitively today. So.
Speaker Change: We can achieve the ambitious share gains and uptake, but if need be we do have price latitude on those products and interventional.
Speaker Change: Perfect.
Speaker Change: And then maybe just lastly, I know you talked a little bit about some of the moving parts there, but just to clean it up a little bit can you sort of lay out this move from 23% to 24% in the guide to 24% or as we think about heading into fiscal 2006 in the high 20% bogey that you've laid out in the past just how much removal of blood center.
Speaker Change: Ah represents.
Speaker Change: At least this year and how we should think about kind of the apples to apples movement from I'm, sorry, not blood center, but whole blood the apples to apples movement on margins from the sale of whole blood.
Speaker Change: Yeah, Andrew I'm going to let James walk you through the math, but let me say this at the outset.
Speaker Change: Because I remember the conversation is pretty vividly after we did our long range plan and provided guidance high.
Speaker Change: High twenties for end of fiscal 'twenty six.
Speaker Change: One comment I think we received from you and others was Wow people don't do that they don't grow a 1000 basis points on their operating income and a four year period.
Speaker Change: Is that realistic cannot be done.
Speaker Change: And I think in a quarter, where we're not living up to our own high aspirations with regards to hospital revenue yet you still see 25, seven and I think the reason for that first and foremost as James said at the beginning of the year. When we guide it is gross margin and within gross margin. It is both.
Speaker Change: Mix and volume, there's productivity and theres price with the innovative new products, but its a gross margin story then passes through our P&L in the quarter. We had some some favorable opex and Thats just a function of pay for performance and the fact that we're not where we need to be across the portfolio.
Therefore.
Speaker Change: Incentive comp reflects that but we think this is very sustainable and this is our long range plan at work. This is the impact you can expect from this portfolio and company transformation, but I will let James give you the math, yes sure. Thanks, Thanks, Chris So.
Speaker Change: Overall.
Speaker Change: If you look at our year to date operating margin through Q3, its at 23, 7%. So we expect Q4 to <unk>.
Speaker Change: Had some more benefit to that.
Speaker Change: Q4 should be.
Speaker Change: At least.
Speaker Change: Q3 is that in.
Speaker Change: Maybe a bit.
Speaker Change: It's better.
Speaker Change: Overall.
Speaker Change: And the drivers there are the same it's the same things that I continued to talk about as we convert plasma centers.
Speaker Change: We have higher margins there for sure.
Speaker Change: The mix issue as more and more of our.
Speaker Change: Revenue.
Speaker Change: Comes a hospital revenue.
That's a tailwind for us as well so those are the key drivers as we get into Q4, and then even beyond as we get into fiscal 'twenty six on your question on whole blood.
Speaker Change: It's certainly helpful as well and.
Speaker Change: We look at that is around 30 to 40 basis points on operating margin.
Speaker Change: In terms of improvement overall.
Speaker Change: Great I'll leave it there thanks guys.
Speaker Change: Thank you. Our next question comes from Joanne Wuensch with Citi. Your line is open.
Hey, Good morning. This is Anthony on for Joanne Thanks for taking our questions.
Speaker Change: Are you able to share a little bit more in detail what steps, you're taking with the op sensitive businesses just to get those back to your targets is it just resourcing salesforce reallocation is there going to be more hiring just spending more detail it would be helpful.
Speaker Change: Good afternoon, and thanks for the question I'm happy to add some more color there.
I wanted to be clear Psa.
Speaker Change: Powerful and as disruptive as it is the primary challenge, we're facing with Enzo ATM.
Speaker Change: <unk> that we're using and so to augment RF when the RF is switched over to PSA.
Speaker Change: Business goes away and that's just the reality of the market. However, we step back from all of this.
Speaker Change: Even the leading PFA suppliers are talking about converting up to 60% of the market in our model we had them at 65%. So what we are looking for is that remaining one third of the market, where RF is the modality of choice or in combination with.
Speaker Change: With DSA.
Speaker Change: Certain use cases and so.
Speaker Change: When we acquired the product.
Speaker Change: Year ago, It was doing roughly 9%.
Speaker Change: 9% of the procedures, if we can grow that 9% to 15% one five we are more than successful in success.
Speaker Change: The metrics, we think is the most appropriate therapy, we think it's the right thing for patients and their physicians, but quantitatively.
Speaker Change: <unk>, it's a double digit ROIC in year three so what we need to do now is identify the RF.
Speaker Change: As it exists in the account they don't want an account goes PSA it rarely is 100%.
Speaker Change: So how do we make sure that Enzo is being added to RF in the remaining percentage whatever that is in some cases, that's caused us to go beyond the 600 and Thats fine we have the capacity to do so.
Speaker Change: Our ability to train our folks to find that opportunity to have the upstream discussion about which modality or you're seeing and if it's RF at Enzo because RF and Enzo together is every bit as fast it is for sure as safe and it costs about <unk> as much too.
Speaker Change: The center into the hospitals. So there's a very strong use case to be made we need to make sure that our commercial and clinical teams are fully <unk>.
Speaker Change: Trained and have ample resources to be able to have those discussions crashed through the noise get to the vac committees and get the product approved and.
Speaker Change: These are all normal and addressable challenges it helps that we're making the additions we are two feet on the street and the upgrade in our training as such but.
Speaker Change: We were probably overly ambitious in terms of how fast we can make all that happen. We don't back off of the original expectations. We don't back off of the fact that these are attractive products and have an important role to play in the market, we need to up our game on execution and Thats, both resources and mind share.
Alright, that's helpful and then on the.
Speaker Change: The Japanese Red Cross win is there any impacts from that this quarter and could you maybe characterize what that could contribute moving forward.
Speaker Change: No.
Speaker Change: We called it out in the quarter because it was a major milestone achievement for us.
It will take several years to implement we have a large volume of business with the Japanese Red Cross today this will be.
Speaker Change: A reconfiguration and a long term commitment there.
Speaker Change: We think this is really an FY 'twenty seven and beyond commercial impact, but it speaks to.
Speaker Change: Does that mean red crosses out very long duration largest non U S based customer, they're incredibly rigorous and their assessment of technology and we're proud that in a head to head comparison with <unk>.
Speaker Change: The market. They came back and said this is a superior plasma collection system. This is the system, we want 100% of our collections being done on over essentially the next decade, and so we called it out because it is a big win for that team and it is an important proof point.
Speaker Change: What we're putting in the market is a winning platform.
Speaker Change: We will be successful against our bold aspiration for majority share.
Speaker Change: Okay. Thank you.
Speaker Change: Thank you.
Speaker Change: Next question comes from Mike Matson with Needham <unk> Company. Your line is open.
Mike Matson: Yes, thanks for taking my questions.
Mike Matson: Just wanted to ask more plasma. So you had this multi year period, where you had some innovations with nexis persona.
Mike Matson: You've got some pricing benefit from those things it sounds like at least with regard to those two that's largely almost done.
Mike Matson: And I know you still have express plus but is this going forward as we look into fiscal 'twenty and beyond are there new innovation and new product launches plan. They can.
Additional price increases in that business beyond just the pure volume growth in collections.
Mike Matson: Yes, Mike Thanks for the question and Youre right with the upgrades. This quarter, we will largely have achieved a rollout of this platform and successfully achieve premium pricing against that superior innovation, we're far from done and one of the things. We're excited about is the partnership we have.
Mike Matson: Across our leading collector customers, where we go next.
Mike Matson: Not done with yield enhancements, we've started the science, we have the benefit of getting data across 80% of the U S collection market, we know over decades.
Mike Matson: Experience now what the upper limits in yield or we will go there and that will probably be the next thing you hear the company talking about explicitly as appropriate we're not done with speed.
Mike Matson: Our equipment can go faster and at the end of the day will bump up against the natural limits of the human anatomy in terms of how fast we can return red cells and.
Mike Matson: In platelets to our donors, but if customers want more procedure speed, where there I think the third thing I would highlight which touches upon door to door speed and really the ultimate differ.
Mike Matson: A differentiating advantage which is.
Mike Matson: Employee and donor satisfaction, we have 80% share of the U S market on our donor management systems and that gives us visibility and an opportunity to really influence procedure sop and whether it's helping the centers operate more productively or make more targeted outreach to.
Mike Matson: Individual donors are just driving phlebotomist and donor satisfaction that that is the most elastic and opportunistic piece of our offering and we're not just the best at doing that Mike. We're the only ones doing that on a proprietary basis. So from our vantage point, that's that's the unmatched.
Mike Matson: <unk> potential and we've really turned our attention on that software SaaS digital AI is just a really exciting frontier for us and stay tuned we'll have more to say as we bring those products to market over the coming quarters and years.
Mike Matson: Okay, great. Thanks, and then just wanted to ask one on there were a lot of questions already about that date, but I didn't really hear you comment on the international launch of SK. So can you just give us an update there in terms of how that Kimberly.
Kimberly: Yes, the international piece is a very positive contributor to our growth, particularly in Japan.
Mike Matson: <unk> is extraordinarily safe.
Mike Matson: Successful in securing not just approval, but very favorable reimbursement on that safety and efficacy profile. So Japan continues to still be.
Mike Matson: Really nice contributor to our growth Europe has gone slower.
Mike Matson: It's a different starting point theyre much more using suturing as a base and there's some vagaries around reimbursement that makes our powerful same day discharge more nuanced we've addressed that.
Mike Matson: Began to build out of our physical presence in those markets, we expect Europe to be very successful going forward, particularly as it adopts new modalities, but it's a work in progress for us it's delivering against our plans, but it's a more modest contributor.
Speaker Change: Okay got it thanks.
Speaker Change: Thank you. Our next question comes from Craig Bijou with Banc of America Securities. Your line is open.
Craig Bijou: Hi, Good morning, Thanks, guys for taking the questions wanted to ask a couple of follow ups. So on.
Speaker Change: Plasma.
And I appreciate some of the moving parts, but it sounds like volumes were better.
Speaker Change: Normal sequentially and better year over year than they were in last quarter. So I guess, maybe just help us reconcile the lower guidance for the year and what Youre seeing there and then.
Speaker Change: Maybe when you're when do we expect.
Speaker Change: Rebounding and kind of in growth there assuming CSL.
Speaker Change: The rolls off.
Speaker Change: Yes.
Craig Bijou: The questions Craig from from our Vantage point, we held the guide on plasma last quarter in part because we expect it.
Craig Bijou: A more robust recovery towards above historical seasonal averages.
Craig Bijou: In line with seasonal averages, but not better than that and we also had anticipations were right on track.
Craig Bijou: Center upgrades to the new technology and the price premium there where things are progressing but it's just it's a stepwise progression is on the center conversions competitive share gains they are contributing but based on the conversations we were having at the time and the rollout plans, we thought there would be more.
Craig Bijou: Our opportunity realized in the second half of this fiscal year, what we know now based on this.
Craig Bijou: This meaningful work that has to happen in the centers have to make not one but two changes to their standard operating procedures, one for persona and one for express plus.
Craig Bijou: It's happening the Ritz.
Craig Bijou: Terms are there the opportunity is real it'll be more of an FY 'twenty six.
Craig Bijou: Event for us than we had originally anticipated in the second half of the current fiscal FY 'twenty five so it is very real it's there it will just be.
Craig Bijou: More measured and take place more heavily in FY 'twenty six for us.
Craig Bijou: Got it that's.
Craig Bijou: That's helpful.
And I did want to follow up on <unk>.
Craig Bijou: And maybe a little bit on just specifically on basket not MPP versus XL. So is this is some of the pressure that you saw on the original basket did that start in this quarter, where you're seeing it in in Q2, and then how should we think about the franchise grow.
<unk> for <unk>.
Craig Bijou: Going forward in <unk>.
Craig Bijou: With a mid twenties for MVP and excel.
Craig Bijou: And then just.
Craig Bijou: Yes.
Craig Bijou: What do we what should we expect from the interventional cardiology side when that can returns.
Craig Bijou: <unk>.
Craig Bijou: Yes, so it's been building for a while and I think some of that is the competitive landscape and some of that is the fact that it's the last 15% and therefore, it didn't get as much attention and are rapidly growing.
Craig Bijou: Kind of expanding footprint so.
Craig Bijou: The product works exceptionally well, it's well positioned in that in that sector and while the growth rate PCI procedure growth rate is low single digits. The Tam is one of the largest tam that we have for vascular closure. So we're keen to get after it and return the focus.
Craig Bijou: There.
Craig Bijou: As we are and so I think yes.
Craig Bijou: I like where we're going going forward I think we will be able to deliver against it.
Craig Bijou: Is tied to our overall presence in interventional cardiology and today. The presence has increased its just a relative mindshare is going more heavily into structural heart as we open new accounts, we're pleased with the rate of new account openings.
Craig Bijou: It's a lengthy process it takes real time and real effort on behalf of the commercial team both commercially and clinically and so it's been a little bit of a drain in that regard as we come up to speed and we're able to balance all priorities.
Craig Bijou: We'll be in a much better place, we do still have vivek sure on the horizon and Viv assure the PERC you sell product.
Craig Bijou: <unk> elite will be an outstanding answer for tab or closure, so it'll improve but by its presence it'll improve our focus on closure more broadly in the interventional cardiology. That's all part of the original strategy. So we're we're keen to get basket to join the party.
Craig Bijou: And get back in and delivering fully we think what we'll do eventually with perky seal what we're doing with Savi wire should be highly synergistic, it's a common call point.
Craig Bijou: And we just need to make sure we have adequate resources there to deliver in terms of your question I wanted to start how do we think about I guess, what I would offer is if you go back and look over the course of our fiscal 'twenty five you'd see the growth rate for MVP and.
Craig Bijou: MVP XL has tracked really over the prior two quarters in the mid Twenty's. So thats you can separate out the basket piece from that it's been a drag relative to that performance and candidly I think the mid <unk> is a good number but we can do better.
Craig Bijou: And part of that's the Resourcing level and the attention where given the full family of products.
Speaker Change: Got it thanks for taking the questions.
Speaker Change: Thank you. Our next question comes from Michael Pitofsky with Barrington Research. Your line is open.
Michael Pitofsky: Hey, good morning, a number of my questions not surprisingly, there's already been a house, but Chris I was wondering if you could just talk about and its almost sort of circles back to like the Super Bowl. These coaches certainly have sort of priorities of things they want to do it within their game plan for <unk>.
Michael Pitofsky: Monday and I'm just curious so if you look over not just not just the next five quarters too.
Michael Pitofsky: Fiscal 'twenty six but over the over the next few years what are the things that are within your control you can't control Trump's tariffs or some of these.
Michael Pitofsky: Other things in terms of evolution of procedures et cetera, but the things that are within your control what are the top 234 things that hey, this is within our control.
Michael Pitofsky: These are priorities that if we execute we will create long term shareholder value.
Michael Pitofsky: Yes, Thanks, Mike look I am not sure I can do the the.
Speaker Change: Super Bowl analogy Justice.
Michael Pitofsky: Think about.
Michael Pitofsky: Human at X and the investment thesis behind that.
Michael Pitofsky: What's transpired over the last three years.
Michael Pitofsky: Our winning and plasma we are committed to plasma we will come out the other side very soon.
Michael Pitofsky: The majority share worldwide and a demonstrated ability to not only drive adoption in advance productivity, but get appropriately compensated for that innovation. So we are very bullish on plasma in the collections business more broadly as an engine of EBITDA for our coop.
Michael Pitofsky: <unk> growing in the high single digits throwing off meaningful profit and cash flow.
Michael Pitofsky: We're using that the proceeds of that business the stability in the door ability of that business to drive diversification and expansion into what is now our largest business in med search.
Michael Pitofsky: Interventional technologies, it's blood management technologies whatever comes next when we're satisfied we're delivering against this opportunity and that has the potential to grow double digits and we will look like a traditional med surge business with gross margins in excess of 70%.
Michael Pitofsky: Rapidly expanding operating income margin.
Michael Pitofsky: And better and so.
Michael Pitofsky: That's that's the play and I think as some of you guys are summarized in prior notes you don't see.
Michael Pitofsky: Mid teens or better organic growth.
Michael Pitofsky: And an expansion in profitability when we guided to the LR peak in June of 2022, we have just finished the year, where we earned $2 58 per share today's guidance that we're reaffirming has us at $4 60, a share more than $2 improvement.
Michael Pitofsky: And 80% build on that with one year remaining in the LP that is the power of the portfolio evolution.
Michael Pitofsky: And the company transformation that's behind it we've got this durable engine and that's going to keep humming given our leadership position. There and then we're going to intelligently expand organically and inorganically to create them at scale med surge business that has the ability to propel the company's growth.
Michael Pitofsky: <unk> high single digits with the associated profitability I think.
Michael Pitofsky: A lot of that the dust will settle and a lot of the noise will fade and I think sitting here certainly this time next year it'll be very obvious the transformative power of the impact.
Speaker Change: This RFP at work.
Michael Pitofsky: Thank you.
Speaker Change: Thank you. Our next question comes from Larry Solow with CJS Securities. Your line is open.
Larry Solow: Good morning, or good afternoon, guys I'm just kidding.
Speaker Change: A long haul here lots of moving parts and most of my questions like Mike have been answered I guess, maybe with all the moving parts I could just give a quick summary, im reading things so plasma Chris it sounds like.
Speaker Change: Basically essentially in line with expectations collections, we know it's been a little slower. This year no reason to believe they are not going to pick up just based on the capacity build outlook.
Speaker Change: And it sounds like you're you're transitioned.
Speaker Change: Express ball in pursuing are all on target. The mid you get a little more of that benefit next year, but otherwise nothing has really changed there.
Speaker Change: Fair to say on the plasma side, plus a couple of market share gains you called out.
Larry Solow: Yes, I think you've got it exactly right Larry.
Speaker Change: Kudos to that team they've used this.
Speaker Change: Short term lull in the growth rate of plasma collections to expedite the conversions.
Speaker Change: Fully on track to be completed and uptick the expansion of share with us.
Speaker Change: The largest customers both U S and globally, so stay tuned for more on that but I think that this bodes very well for the recovery that comes in terms of the ongoing uptick in demand.
Speaker Change: And the Biolife Griffith that you called out. So those are those are extensions and there actually incremental more centers is that correct.
Speaker Change: Technically they are new agreements.
Speaker Change: Long duration.
Speaker Change: And.
Speaker Change: There are all based on.
Speaker Change: Full scale adoption. These are agreements that were written for Nexus with persona and express plus there are some commitments around ongoing development that will do together going forward.
Speaker Change: They are global in scope as robust internationally as they are in the U S.
Speaker Change: Okay.
Speaker Change: Color just I know last couple of quarters, you've been talking obviously with MVP XL.
Speaker Change: Talking about intrinsic PSA, but also the left material appendages any any color on the left arterial appendages side and also just on the ablation side access.
Speaker Change: Good points has there been any material change or any color on that.
Speaker Change: No.
Speaker Change: We have the label for left atrial appendage, and that's really helped us because it's given our folks the ability to go in and have the direct conversation so as as the leading companies continue to drive adoption of that therapy.
Speaker Change: Right, there with them and we will see the appropriate uptake of the product works exceptionally well in those use cases, so no I think we've got the ability to.
Speaker Change: We sit when I think about the Tam, we are less than or right at 50% utilization that still means half of the closure procedures and ablation. For example are being done with manual compression our suturing.
Speaker Change: This technology is that we had 80 share of the half that's convert it we need to go get the other half and it's entirely a utilization game at this point, it's about our footprint, it's about our clinical presence and helping that the half of the market that's not.
Speaker Change: At the party to get there because there's just a better treatments and better outcome for their patients and typically the competition that we have attracted typically.
Speaker Change: That helps the category it helps drive the medical adoption message and we would expect that over time here as the excitement around PFA normalizes. So.
Speaker Change: Stay tuned, but we think there's meaningful room to run in both left atrial appendage and a fit with the product portfolio we have today.
Speaker Change: Right and then just in terms of Viv assure the purchase sale you mentioned.
Speaker Change: What's sort of the next milestone that we can look for.
Speaker Change: And that program.
Speaker Change: FDA submission right you if you go back the TCT the patch trial readout truly excellent results.
Speaker Change: <unk> worked with them over the last two months to kind of scrub and clean up the data and get it prepared for submission they've.
Speaker Change: <unk> done all the right things in terms of pre submission dialogue with FDA in preparation so fully expect that submission to go on probably this month and then that will start a clock offer FDA review and take the next steps in partnership with them.
Speaker Change: Sure.
Speaker Change: Got it if I could just squeeze one more James on the margins it sounds like.
Speaker Change: Well on the way.
Speaker Change: <unk>, a little bit better this quarter, maybe just from some benefit of a little bit lower on the variable comp.
Speaker Change: But everything it sounds like it's moving in the right direction for you is that all.
Speaker Change: Fair to say.
Speaker Change: Yes, that's fair.
Speaker Change: Pleased with the margin performance and.
Speaker Change: As I said earlier, we should expect.
Speaker Change: This level a bit better next quarter with the stuck with those continuing drivers. The story is playing out pretty much like we thought it was.
Speaker Change: Great. Thanks, guys I appreciate it.
Speaker Change: Thank you thanks a lot.
Speaker Change: I'm showing no further questions at this time. This does conclude our question and answer session and you may now disconnect. Thank you for your participation everyone have a great day.
Speaker Change: Okay.
Speaker Change: [music].
Speaker Change: Okay.